Notice of Intent to Sole Source – CARDINAL HEALTH 414, LLC– radiopharmaceuticals
Archived on October 20, 2026. Original response deadline: . Full description on SAM.gov.
Overview
- Response deadline
- 12:00 PM EDT
- Posted
- October 13, 2026
- Notice type
- Presolicitation
- NAICS
- 325412: Pharmaceutical Preparation Manufacturing
- Agency
- Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH
Notice details
- Office
- NATIONAL INSTITUTES OF HEALTH OLAO
- Place of performance
- Bethesda, Maryland, 20892
- Last updated
- Oct 28, 2026
- First published
- Last updated on SAM.gov
Identifiers
- Solicitation number
- NOI-OD-27-000001
- Notice ID
- 8feb133f7d0241febaacc4a342ad1e25
Description
This is a notice of intent, not a request for a quotation. A solicitation document will not be issued and quotations will not be requested.
This procurement is for a purchase order NTE $900,000 for FDA-approved radiopharmaceuticals for patient care by the Nuclear Medicine Division, Department of Radiology and Imaging Sciences at the NIH Clinical Center. CARDINAL HEALTH is a reputed and reliable FDA and US NRC vetted supplier of the required radiopharmaceuticals by the Clinical Center. Based on the past 25 years of contracting with this vendor, this vendor is the only acceptable vendor because they provide a comprehensive list of radiopharmaceuticals that uniquely meets the patient needs of the NIH Clinical Center. They are the only provider that can supply all radiopharmaceuticals that emit gamma, positrons, beta and/or alpha radiations. They also use a patented tungsten delivery system for dispensing the high energy positron radiopharmaceuticals. This system minimizes radiation exposure to the staff and the public, as well as meeting the weight standard that reduces the potential weightlifting injuries to the staff.
This acquisition is being conducted using policies unique to the Federal Acquisition Regulation (FAR) Part 13 –Simplified Acquisition Procedures, Subpart 13.500 This subpart authorizes the use of simplified procedures for the acquisition of supplies and services in amounts greater than the simplified acquisition threshold but not exceeding $9 million ($15 million for acquisitions as described in 13.500(c)), including options, if the contracting officer reasonably expects, based on the nature of the supplies or services sought, and on market research, that offers will include only commercial products or commercial services. Contracting officers may use any simplified acquisition procedure in this part, subject to any specific dollar limitation applicable to the particular procedure. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements.
Comments to this announcement, referencing this posting number, may be submitted to the NIH, Clinical Center, Office of Purchasing and Contracts, prior to the closing date specified in this announcement, to the attention of Ryssa Nix, Contract Specialist via email to Ryssa.nix@nih.gov by close date.
Notice Type: Notice of Intent
NAICS Code: 325412
PSC Code: 3650
Posted Date: 10/13/2026
Close Date: 10/19/2026 12pm EST
End User IC: Clinical Center
POC Name: Ryssa Nix
Email Address: Ryssa.nix@nih.gov
Award Overview
No prior contract identified
No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.
Contacts
Contracting Officer
Primary Contact
Documents
Files (1)
- Download
NOI to sole source above SAT.docx
23 KBAdded in Presolicitation version 3Posted
Lifecycle
- 3Version 3PresolicitationArchivedCurrent
Notice of Intent to Sole Source – CARDINAL HEALTH 414, LLC– radiopharmaceuticals
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
Central Alabama Veterans Healthcare System Radiopharmaceuticals | 46% | Special Notice | 09/15/2026 |
Acquisition Description: This is a Notice of Intent, not a request for proposal. The National Institute of Health, Clinical Center (NIH-CC) intends to negotiate on an other than full and open competition basis with Cardinal Health. This requirement will be sole sourced to Cardinal Health under FAR 13.501(a) or 8.405-6 (b) - sole source requirements. The National Institutes of Health (NIH) Clinical Center (CC) (NIH-CC or “Program”) is a clinical research hospital providing all medical services for patients participating in human research protocols of the NIH. The CC Pharmacy department provides a range of pharmaceutical care services to inpatients and outpatients enrolled in clinical trials. The CC Pharmacy department is responsible for acquiring the supply of medications required for patient care. The NIH-CC has a pharmacy center that requires Sirturo (Bedaquiline) drug tablets for patient care. Sirturo is supplied in the following forms: 100 mg tablets in 188 count bottles and 20 mg tablets in 60 count bottles. Various different quantities are needed every year. Based on Program’s purchase history in the past, and factoring in the anticipated patient enrollment, Program expects to need approximately 12 - 36 bottles of each type of Sirturo® bottles per year. Justification: Only this Sirturo medication can be accepted as there are no substitutes for this medication. The manufacturer (Janssen Therapeutics) has designated Cardinal Health (DBA Metro Medical Supply) as the sole distributor of Sirturo in the U.S. Previous acquisitions and research indicated that this requirement should be a sole source requirement. For the previous acquisitions, Notice of Intent notices were posted on SAM.gov. Cardinal Health/Metro Medical was the only sole source provider. In order to confirm this is still applicable, this requirement was previously posted on SAM.gov as an RFQ under full and open competition under RFQ-CC-24-008485. No other companies responded, and it was confirmed by this posting that they are the sole source vendor. Previous acquisitions and research revealed this requirement should be a sole source requirement. More recently, a Request for Quotes was posted under RFQ-CC-24-008485 and it was reconfirmed that Cardinal Health/Metro Medical is the sole source vendor as they are the official authorized reseller of this equipment via their relationship with the manufacturer. Thus, Cardinal Health/Metro Medical is the only responsible and authorized source for Sirturo. Requirements: SIRTURO (BEDAQUILINE) 100 mg tablet in 188-count bottles (NDC# 59676070101) SIRTURO (BEDAQUILINE) 20 mg tablet in 60-count bottles (NDC#59676070260) Period of performance/Date of Delivery: Within 30 days of award, or mutually agreed upon. Place of Performance or Delivery: Place of Performance: NIH Clinical Center in Bethesda, MD The statutory authority for this sole source requirement is 41 U.S.C. 1901 (a) (1) as implemented by FAR 13.106-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide the required may submit a capability statement that will be considered by email (subject line to reference NOI-27-000056) by 04:00 PM eastern standard time on 11/11/2026 to: lu-chang.lu@nih.gov All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government. | 46% | Pre-Solicitation | 11/11/2026 |
Sources sought notice for VISN 2 Downstate General Radiopharmaceuticals. | 44% | Market Research | 11/17/2026 |
44% | Awarded | Open | |
44% | Awarded | Open |
Additional Details
Solicitation Number
NOI-OD-27-000001
Archive Date
Oct 20, 2026
Office Address
BETHESDA, MD, 20892